CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Ceragenix Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Ceragenix Pharmaceuticals Inc
1444 Wazee Street
Suite 210
Phone: (720) 946-6440p:720 946-6440 Denver, CO  80202  United States Fax: (302) 421-5753f:302 421-5753

On 1/17/2014, the U.S. Securities and Exchange Commission revoked the registration of each class of registered securities of Ceragenix Pharmaceuticals Inc for failure to make required periodic filings with the Commission.
This company is no longer actively traded on any major stock exchange.

Business Summary
Ceragenix Pharmaceuticals, Inc. is a medical device company focused on infectious disease and dermatology. It has two base technology platforms each with multiple applications: Ceragenins and Barrier Repair. The Ceragenin technology covers the composition of matter and use of a range of small molecule, positively charged aminosterol compounds. The compounds mimic the activity of the naturally occurring antimicrobial peptides that form the body’s innate immune system and several of these candidates are in pre-clinical development. EpiCeram is a prescription only product intended for use to treat dry skin conditions and to manage and relieve the burning and itching associated with various types of dermatoses, including atopic dermatitis (eczema), irritant contact dermatitis, and radiation dermatitis. The products of the Company include Cerashield Antimicrobial Technology, EpiCream and NeoCream.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/200912/31/2009YesYesYes-Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer Steven S.Porter 62 5/1/2005 5/1/2005
Chief Financial Officer, Director Jeffrey S.Sperber 47 5/1/2005 5/1/2005
Vice President - Corporate Development Russell L.Allen 65 6/1/2005 6/1/2005

Business Names
Business Name
Ceragenix Corporation
CERAGENIX PHARMACEUTICALS, INC.

General Information
Number of Employees: 5 (As of 12/31/2009)
Outstanding Shares: 18,303,293 (As of 4/12/2010)
Shareholders: 800
Stock Exchange: OTC
Federal Tax Id: 841561463
Fax Number: (302) 421-5753


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023